IES MCRC
VALUE ADDITION THROUGH EDUCATION

PharmaVISION

PharmaVISION

Educating Minds, Empowering Pharma

AUGUST 2025

Pharma and Healthcare Insights

Published by

PHARMA CLUB

IES's Management College and Research Centre, Mumbai

PharmaVISION

NOVO NORDISK'S WEGOVY, MOUNJARO SALES IN INDIA DOUBLE ON MONTH IN JULY

Sales of anti-obesity drugs Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) doubled in India within a month of launch, according to Pharmarack. Wegovy, launched in June, sold 5,000 units worth ₹70 crore in July, while Mounjaro clocked 157,000 units worth ₹470 crore.

In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes.
Mounjaro's sales have soared 15 times since March, when the drug was launched in India.
Obesity and diabetes management may soon become a "blockbuster class" in India, reshaping therapy priorities for both MNCs and domestic players.

Source: THE ECONOMIC TIMES

> “**Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market**,” Pharmarack's Vice President (Commercial) Sheetal Sapale said in a statement.

INDIAN PHARMA MARKET REGISTERS 7.9 PERCENT GROWTH IN JULY

The Indian Pharmaceutical Market (IPM) registered 7.9% growth in July 2025, driven by strong demand in chronic therapies. Cardiac (+14.1%) and anti-diabetes (+9%) segments led the growth, reflecting India's rising non-communicable disease (NCD) burden. Respiratory (+9.2%), urology, and oncology also contributed double-digit gains.

Source: MD Bureau

From pharmacy to innovation hub: Why India needs a regulatory revolution in biotech

Biocon's Kiran Mazumdar-Shaw argued India's biotech growth is being stifled by outdated, fragmented regulations. She called for agile, tech-enabled frameworks including AI-driven approvals, adaptive trials, and real-world evidence pathways.

Source: THE ECONOMIC TIMES

US tariff heat: Fitch says Indian firms face limited direct hit; pharma sector seen at risk if duties widen

The U.S. imposed 50% tariffs on Indian imports tied to Russian oil, but exempted pharmaceuticals due to America's heavy reliance on Indian generics (40% of U.S. pharma imports).

Source: THE TIMES OF INDIA

INDIAN PHARMA AND HEALTHCARE FUNDING DROPS 82% IN AUGUST 2025 TO $47 MILLION

As per Tracxn's report, India's pharma and healthcare sectors witnessed a major funding slowdown in August 2025, attracting only $47 million across seven rounds, marking an 82.83% decline from July 2025's $274 million and an 82.26% drop compared to August 2024. Private equity funding dominated the landscape, accounting for 76.5% of total investments, while early-stage and seed-stage funding contributed 21.3% and 2.2%, respectively.

The largest deal of the month came from Aragen, which raised $36 million, followed by Eyestem ($10 million), Aethermt ($0.5 million), QRL Bioscience ($0.3 million), and Cureous ($0.2 million). Investors such as Anthill Ventures, Gujarat Venture Finance, and Inflection Point Ventures were active participants, though the overall trend pointed to smaller deal sizes and a sharp decline in funding momentum across the sector.

Source: EH News Bureau

ELI LILLY SAYS VERZENIO EXTENDED SURVIVAL IN LATE-STAGE BREAST CANCER TRIAL

Eli Lilly (NYSE: LLY) announced that its FDA-approved breast cancer drug Verzenio (abemaciclib), when combined with endocrine therapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) in the Phase 3 monarchE trial. The global study enrolled over 5,500 patients with hormone receptor-positive (HR+), HER2-negative, node-positive, high-risk early breast cancer.

Results showed that Verzenio not only improved OS—a key secondary endpoint—but also maintained benefits in invasive disease-free survival, the study's primary endpoint. Lilly emphasized that these results confirm Verzenio's role as the standard-of-care for high-risk, early-stage breast cancer patients. The company plans to present the detailed data at an upcoming medical conference, submit it to a peer-reviewed journal, and engage with global regulators regarding the findings.

Source: Seeking Alpha

STRATEGIC BUSINESS UPDATES

AbbVie to acquire Gilgamesh Pharmaceuticals' bretisilocin for $1.2 billion

AbbVie entered a definitive agreement to acquire Gilgamesh Pharmaceuticals' bretisilocin, a next-generation psychedelic-inspired therapy for major depressive disorder, in a deal worth up to USD 1.2 billion. Clinical studies have shown rapid antidepressant effects with sustained benefits and fewer side effects than traditional psychedelics.

The acquisition reflects Big Pharma's growing interest in novel psychiatric treatments, a space gaining traction globally. For AbbVie, this strengthens its neuroscience pipeline after recent setbacks in schizophrenia R&D. The move positions AbbVie as an early leader in the potentially disruptive psychedelic therapies segment.

Source: Abbvie News Center

Lupin & Sandoz Seal Biosimilar Licensing Deal

Lupin announced a global licensing partnership with Sandoz for its ranibizumab biosimilar, used in treating retinal disorders like AMD and diabetic macular edema. Under the deal, Sandoz will manage commercialization across the EU, Canada, Switzerland, Australia, and select Asian markets, while Lupin retains manufacturing and regulatory responsibilities.

The collaboration strengthens Lupin's global biosimilars portfolio and enhances patient access to affordable biologics. For Sandoz, the addition reinforces its ophthalmology pipeline. The deal highlights how Indian companies are transitioning from generic dominance to becoming global players in complex biologics.

Source: Lupin Limited

STRATEGIC BUSINESS UPDATES

Gland Pharma Wins FDA Nod for Vasopressin Injection

Gland Pharma secured U.S. FDA approval for ready-to-use Vasopressin injection in 5% dextrose (RTU vials), used in treating vasodilatory shock. The product is bioequivalent to Vasostrict and recorded U.S. annual sales of ~$45 million (ending June 2025). Gland also received tentative approval for a lower-dose version.

This approval enhances Gland's specialty injectable portfolio and reinforces India's position as a global hub for complex generics in critical care. Regulatory wins such as this improve India's reputation for quality manufacturing while boosting export-driven revenues.

Source: Gland Pharma Limited

Samsung Launches Next-Gen Mobile CT Scanners in India

Samsung India, along with subsidiary NeuroLogica, introduced advanced mobile CT scanners including CereTom Elite, OmniTom Elite, and BodyTom 32/64. These portable devices are designed for ICUs, emergency rooms, oncology, and pediatric care, enabling bedside diagnostics while reducing infrastructure needs. With AI-driven capabilities and seamless hospital integration, they promise faster diagnoses and wider access, especially in underserved regions.

Insight: This marks Samsung's deeper push into healthcare technology in India, bridging urban-rural gaps and redefining diagnostic imaging delivery.

Source: Samsung Newsroom India

Indian Pharma Market – August 2025

IPM Overview

		TSA	SSA
MAT Aug'25	Value	Rs. 241,473 Cr	Rs. 2,03,331 Cr
	Growth %	7.7 %	7.3 %
Month Aug'25	Value	Rs 21,843 Cr	Rs. 18,395 Cr
	Growth %	8.1 %	7.7 %

Top Companies

	Val Aug'25	MS Aug'25
(SUN*)	1690	7.74
(ABBOTT*)	1369	6.27
CIPLA	1132	5.18
MANKIND	1050	4.81
ALKEM*	898	4.11
(INTAS*)	801	3.67
MACLEODS	778	3.56
(LUPIN)	731	3.35
(TORRENT)	724	3.32
(DRL)	689	3.15

10 contributing therapies



- Mounjaro emerged as the Star Brand, generating ₹118 Cr in August and becoming the fastest-growing product.
- Macleods strengthened its position in the Top 10, showing strong upward momentum.
- Aristo, Glenmark, Sanofi, and Himalaya improved their ranks in the Top 25, reflecting competitive dynamism among mid-tier players.
- Multinational companies grew 11.4%, clearly outpacing Indian companies at 7.5%, driven by innovative launches.

Source: IQVIA Market Reflection Report August 2025

August 2025

Issue No. 01

PGDM-Pharmaceutical Management

PGDM Program is a meticulously conceived industry oriented program, approved by AICTE, NBA accredited and Equivalent to MBA by AIU. It is a 2 Year Full Time Program consisting of 6 terms. PGDM-PM is a meticulously conceived industry oriented program, approved by AICTE. It offers a complete insight into the Pharmaceutical sector.

Editorial Team:

Anchal Israni
anchal.israni24@ies.edu
Phone no: 8850699342

Prapti Nagdeve
prapti.nagdeve25@ies.edu
Phone no: 93241 22779

Rohit Rane
rohit.rane24@ies.edu
Phone no: 7021304643

Sunny Roy
sunny.roy25@ies.edu
Phone no: 8850790128

Sanika Narvankar
sanika.narvankar24@ies.edu
Phone no: 7249748847

Janhavi Narvekar
janhavi.narvekar25@ies.edu
Phone no: 992070698

Kiran Yadav
kiran.yadav24@ies.edu
Phone no: 7738192500

Sachi Israni
sachi.israni25@ies.edu
Phone no: 8850687300

Ajay Kharate
ajay.kharate24@ies.edu
Phone no: 8381058570

Nishant Choudhari
nishant.choudhari25@ies.edu
Phone no: 9326191028

General Enquiry Address: IES MCRC "Vishwakarma" M.D. Lotlikar Vidya Sankul, 791, S. K. Marg, Bandra Reclamation, Mumbai - 400 050

Registrar office / Admin Office no. - 022 - 5000 1725/ 5000 1785

For any other enquiry - ies.mcrc@ies.edu/ registrar.mcrc@ies.edu